Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 18/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355215 | 0.93 | PTGES (0.86) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL4361125 | 0.91 | PTGES (0.84) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL4367630 | 0.89 | PTGES (0.81) | PTGESJAK2JAK3 | |
| SCHEMBL1758282 | 0.88 | PTGES (1.00) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL13631665 | 0.85 | PTGES (0.76) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL4361691 | 0.85 | PTGES (1.00) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL4360603 | 0.85 | PTGES (0.75) | PTGESJAK2JAK3 | |
| SCHEMBL4049140 | 0.84 | PTGES (0.91) | PTGESJAK2PIM1CSNK2A2CSNK2B | |
| SCHEMBL3956389 | 0.83 | PTGES (0.72) | PTGESJAK2 | |
| SCHEMBL4353166 | 0.82 | PTGES (0.70) | PTGESJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| WO-2007095753-A1 | 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES | MERCK FROSST CANADA LTD. (CA) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | PTGES, PTGS1, PTGES2 | PTGES 1/4885JAK2 1520/4885PIM1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.